A Prospective, Multi-centric, Open-label, Single-arm, Phase 4 Study to Evaluate the Safety and Efficacy of Canagliflozin + Metformin Hydrochloride IR Fixed-dose Combination as an Adjunct to Diet and Exercise to Improve Glycemic Control in Indian Adult Patients With Type 2 Diabetes Mellitus When Treatment With Both Canagliflozin and Metformin is Appropriate
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Canagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Johnson & Johnson
Most Recent Events
- 16 Aug 2022 Status changed from active, no longer recruiting to completed.
- 29 Mar 2022 Planned primary completion date changed from 28 Jan 2022 to 31 Jul 2022.
- 01 Feb 2022 Planned End Date changed from 29 Aug 2022 to 31 Jul 2022.